BRIDGEWATER, N.J., Nov. 6, 2024
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first
global biopharmaceutical company striving to deliver first- and
best-in-class therapies to transform the lives of patients facing
serious diseases, today announced that management will present at
the following investor conferences:
- Guggenheim's Inaugural Healthcare Innovation Conference in
Boston on Monday, November 11, 2024, at 1:00 p.m. ET.
- UBS Global Healthcare Conference in Rancho Palos Verdes,
Calif., on Tuesday, November 12,
2024, at 11:45 a.m. PT /
2:45 p.m. ET.
- Wolfe Research Healthcare Conference in New York on Wednesday,
November 20, 2024, at 8:00 a.m.
ET.
- Jefferies London Healthcare Conference in London on Thursday,
November 21, 2024, at 8:30
a.m. GT / 3:30 a.m. ET.
These events will be webcast live and can be accessed by
visiting the investor relations section of the Company's website
at www.insmed.com. Webcasts will be archived for a
period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical
company striving to deliver first- and best-in-class therapies to
transform the lives of patients facing serious diseases. The
Company is advancing a diverse portfolio of approved and mid- to
late-stage investigational medicines as well as cutting-edge drug
discovery focused on serving patient communities where the need is
greatest. Insmed's most advanced programs are in pulmonary and
inflammatory conditions, including a therapy approved in
the United States, Europe, and Japan to treat a chronic, debilitating lung
disease. The Company's early-stage research programs encompass a
wide range of technologies and modalities, including gene therapy,
AI-driven protein engineering, protein manufacturing, RNA
end-joining, and synthetic rescue.
Headquartered in Bridgewater, New
Jersey, Insmed has offices and research locations throughout
the United States, Europe, and Japan. Insmed is proud to be recognized as one
of the best employers in the biopharmaceutical industry, including
spending four consecutive years as the No. 1 Science Top
Employer. Visit www.insmed.com to learn more.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
(646)
812-4030
bryan.dunn@insmed.com
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917)
936-8430
michael.morabito@insmed.com
Gianna De Palma
Manager, Investor Relations
(973)
886-2236
gianna.depalma@insmed.com
Media:
Mandy Fahey
Vice President, Corporate
Communications
(732)
718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-november-2024-investor-conferences-302296893.html
SOURCE Insmed Incorporated
